VSC 4 SC AG

4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended 4SC's anti-cancer compound resminostat for designation as orphan medicinal product for the treatment of Hodgkin's Lymphoma (HL), a cancer of the lymphatic system. EMA's orphan medicinal product designation includes a ten-year period of market exclusivity from the date of approval in the European Union (EU) and allows direct access to a centralized marketing authorization and fee reductions. Resminostat, 4SC's lead oncologic compound, already received in July 2011 a positive opinion for orphan medicinal product designation in the EU in the indication hepatocellular carcinoma (HCC), the most common type of liver cancer. Furthermore, resminostat recently obtained orphan drug status in the US for HCC and HL.

As recently reported, in the Phase II SAPHIRE study as a third-line treatment in relapsed/refractory HL patients, resminostat showed a 33.3% overall response rate and a general clinical benefit in 54.5% of patients, demonstrating positive anti-tumour-efficacy and very good tolerability. Furthermore 4SC had published in June 2011 positive interim data from its Phase II SHELTER study with resminostat in HCC patients. The oral pan HDAC inhibitor resminostat is, in addition to evaluation in HL and HCC, currently also being studied in a phase I/II trial in patients with colorectal cancer (CRC).

Dr. Ulrich Dauer, CEO of 4SC commented: 'We are delighted that the EMA has recommended our lead oncology compound resminostat for designation as orphan medicinal product also in Hodgkin's Lymphoma (HL). Based on the positive data from our Phase II SAPHIRE study in HL and on the results of our Phase II SHELTER study in HCC, which are anticipated by the end of this year, we plan to discuss the next development steps with regulatory authorities and potential partners. Consequently we expect the next step to be the planning of a pivotal development programme, especially considering the high medical need and the limited therapeutic options available in the indications addressed with resminostat.'

For further information, please visit www.4sc.com

About Hodgkin's Lymphoma

Hodgkin's Lymphoma (HL) is a cancer of the lymphatic system, which is part of the immune system, and leads to the abnormal growth of lymphatic cells that compromise the immune system's ability to fight infection. The disease can spread beyond the lymphatic systems to other organs. The main causes for the development of HL are still unknown. Recent research shows that this tumour has its origin from a degenerated lymphatic cell, the B lymphocyte. The incidence of HL in 2008 was 11,777 new cases in Europe and 8,220 new cases in the US. The age distribution is bimodal; the first peak occurs between the ages of 15 and 30 years and the second in the seventh decade.

HL is curable in the majority of cases. However, not all patients can be cured and available therapies for this disease can have significant long-term toxicity. Therapy options for HL patients depend on the stage of the disease and number and regions of lymph nodes affected. The first treatment line for HL, after the initial diagnosis, consists of chemotherapy and/or radiation, achieving cure rates of up to 80%. Standard of care for patients with refractory or relapsing disease after initial therapy consists of a salvage therapy comprising a conventional chemotherapy regimen usually followed by stem cell mobilization and subsequent high-dose chemotherapy along with autologous stem cell transplantation. Patients relapsing after second line therapy have a 5-year overall survival rate of only 17% (Source: Sirohi et al., Ann.Oncol., 2008). Since there is no standard of care in patients with relapsed/refractory HL, there is an especially high need to develop novel therapies for these patients.

About Resminostat

Resminostat (4SC-201) is an oral pan-histone-deacetylase (HDAC) inhibitor. HDAC inhibitors modify the DNA structure of tumour cells to cause their differentiation and programmed cell death (apoptosis) and are therefore considered to offer a mechanism of action that has the particular potential to halt tumour progression and induce tumour regression. Resminostat is currently being investigated in the Phase II SHELTER study as a second-line treatment for advanced hepatocellular carcinoma and in the Phase I/II SHORE study as a second-line treatment in colorectal cancer in KRAS-mutant patients. The SHELTER study is expected to report Phase II results in 2011. Initial results of the SHORE study are expected in 2012. The reported Phase II SAPHIRE trial for resminostat as a third-line therapy in Hodgkin's lymphoma is still ongoing as patients are continuing on study therapy in the optional follow-up phase beyond the study's main treatment cycle of 12 weeks. Resminostat is currently partnered in Japan with Yakult Honsha.

About 4SC

4SC (ISIN DE0005753818) discovers and develops targeted small-molecule drugs for the treatment of diseases with a high unmet medical need in various autoimmune and cancer indications. These drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The company's balanced pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical companies. Founded in 1997, 4SC currently has 94 employees and has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.

Legal Note

This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.

  Language: English Company: 4SC AG Am Klopferspitz 19a 82152 Martinsried Germany Phone: +49 (0)89 7007 63-0 Fax: +49 (0)89 7007 63-29 E-mail:

public@4sc.com

Internet:

www.4sc.de

ISIN: DE0005753818 WKN: 575381 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart